CHIR99021, Free Base (CT-99021, GSK-3 Inhibitor XVI, CAS 252917-06-9), >99%

LC Laboratories' Product Number C-6556 - CHIR99021, Free Base (CT-99021, GSK-3 Inhibitor XVI, CAS 252917-06-9), >99% - for research use only. CHIR99021 specifically inhibits glycogen synthase kinase-3β (GSK3β, IC50 = 5 nm) and GSK3α (IC50 = 10 nm), inhibits preadipocyte differentiation (IC50 = 0.3 µM), possibly by blocking induction of C/EBPα and PPARγ, and mimics Wnt signaling in 3T3-L1 preadipocytes. CHIR99021 showed highly selective inhibition of GSK-3α and GSK-3β, with IC50s of 10 nM and 6.7 nM, respectively. It showed a Ki of 9.8 nM for GSK-3β. However, it exhibited an IC50 of 8800 nM for CDC2. CHIR99021 activates glycogen synthase in CHO-IR cells with EC50 of 763 nM. ZDF rats display insulin resistance, glucose intolerance, and mild hyperglycemia. In these rats, a single oral dose of CHIR 99021 rapidly reduced plasma glucose while plasma insulin remained at or below control levels. ZDF rats treated with CHIR 99021 showed significantly improved glucose tolerance with no significant differences in plasma insulin levels compared with control animals. Alsterpaullone, kenpaullone, SB 214763, and SB 415286 not only inhibited GSK-3 potently but also blocked CDKs. In contrast, CHIR99021 showed 350-fold selectivity toward GSK-3 compared to CDKs. GSK-3 is an important intermediate in the pathway from the insulin receptor to the Thymine-rich Insulin Response Element (TIRE). Regulation of gene transcription by insulin totally depends on GSK-3 inhibition. CHIR99021 induced osteoblastogenesis, increased mineralization, and inhibited adipogenesis in ST2 cells. GSK-3 is a regulator of pancreatic beta cell replication and survival, and the GSK3 inhibitor CHIR99021 increased the rate of INS-1E beta cell replication.

• Supplier: LC Laboratories
• Product #: C-6556
• Sku #: C-6556_500mg